Movement Alert｜Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts

Market Focus06-18

On June 18, Innovent Biologics rose 3.07% in regular trading, trading at 77.75 HKD/share, with turnover of approximately 175 million HKD.

On the news front, the biotechnology sector rallied broadly, with AKESO up 6.91%, 3SBIO up 5.04%, Remegen up 4.75%, BeiGene up 4.70%, and SKB Bio up 4.66%, forming strong sector-wide momentum that lifted Innovent Biologics. Additionally, the ongoing EULAR rheumatology conference recently disclosed clinical data on immune resetting therapies for autoimmune diseases, providing academic catalysts for companies with rich autoimmune pipelines. Innovent Biologics, which maintains an extensive portfolio spanning oncology, cardiovascular and metabolic diseases, and autoimmune conditions, stands to benefit from renewed investor interest in the autoimmune therapeutic space.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1103077548?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-18 10:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1103077548","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts","media":"Market Focus","content":"<p><p>On June 18, Innovent Biologics rose 3.07% in regular trading, trading at 77.75 HKD/share, with turnover of approximately 175 million HKD.</p><p>On the news front, the biotechnology sector rallied broadly, with AKESO up 6.91%, 3SBIO up 5.04%, Remegen up 4.75%, BeiGene up 4.70%, and SKB Bio up 4.66%, forming strong sector-wide momentum that lifted Innovent Biologics. Additionally, the ongoing EULAR rheumatology conference recently disclosed clinical data on immune resetting therapies for autoimmune diseases, providing academic catalysts for companies with rich autoimmune pipelines. Innovent Biologics, which maintains an extensive portfolio spanning oncology, cardiovascular and metabolic diseases, and autoimmune conditions, stands to benefit from renewed investor interest in the autoimmune therapeutic space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Innovent Biologics Rises 3.07% in Regular Trading, Biotech Sector Rally and EULAR Conference Data Provide Dual Catalysts\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-18 10:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 18, Innovent Biologics rose 3.07% in regular trading, trading at 77.75 HKD/share, with turnover of approximately 175 million HKD.</p><p>On the news front, the biotechnology sector rallied broadly, with AKESO up 6.91%, 3SBIO up 5.04%, Remegen up 4.75%, BeiGene up 4.70%, and SKB Bio up 4.66%, forming strong sector-wide momentum that lifted Innovent Biologics. Additionally, the ongoing EULAR rheumatology conference recently disclosed clinical data on immune resetting therapies for autoimmune diseases, providing academic catalysts for companies with rich autoimmune pipelines. Innovent Biologics, which maintains an extensive portfolio spanning oncology, cardiovascular and metabolic diseases, and autoimmune conditions, stands to benefit from renewed investor interest in the autoimmune therapeutic space.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01801","symbol_name":"信达生物","start_time":0,"source_url":"","article_id":"1103077548","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1103077548","pubTimestamp":1781749617,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 18, Innovent Biologics rose 3.07% in regular trading, trading at 77.75 HKD/share, with turnover of approximately 175 million HKD.On the news front, the biotechnology sector rallied broadly,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01801":"信达生物"},"translate_title":"动感快讯|信达生物常规交易涨3.07%，生物科技板块涨势和EULAR会议数据提供双重催化剂","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01801":1},"content_text":"On June 18, Innovent Biologics rose 3.07% in regular trading, trading at 77.75 HKD/share, with turnover of approximately 175 million HKD.On the news front, the biotechnology sector rallied broadly, with AKESO up 6.91%, 3SBIO up 5.04%, Remegen up 4.75%, BeiGene up 4.70%, and SKB Bio up 4.66%, forming strong sector-wide momentum that lifted Innovent Biologics. Additionally, the ongoing EULAR rheumatology conference recently disclosed clinical data on immune resetting therapies for autoimmune diseases, providing academic catalysts for companies with rich autoimmune pipelines. Innovent Biologics, which maintains an extensive portfolio spanning oncology, cardiovascular and metabolic diseases, and autoimmune conditions, stands to benefit from renewed investor interest in the autoimmune therapeutic space.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease,conferences","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1103077548","isCrawlerRequest":true}